drugset
Drugs / PF-04991532
last change May 2012 re-read 9 days ago

PF-04991532

Small molecule targets GCK via activation

Developed for
type 2 diabetes mellitus
Investigated by
Pfizer

Trials 11

today NCT01469065 · Ph 1 NCT01469481 · Ph 1 NCT01370343 · Ph 1 NCT01388829 · Ph 1 NCT01369602 · Ph 1 NCT01338870 · Ph 2 NCT01369277 · Ph 1 NCT01336738 · Ph 2 NCT01351129 · Ph 1 NCT01129258 · Ph 1 NCT01102673 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials · 1 met primary
Phase 1 NCT01469065 Dec 2011 → May 2012 type 2 diabetes mellitus Pfizer Completed Met primary
Phase 1 NCT01469481 Nov 2011 — Pfizer Completed No outcome recorded
Phase 1 NCT01370343 Jul 2011 — Pfizer Completed No outcome recorded
Phase 1 NCT01388829 Jul → Aug 2011 — Pfizer Completed No outcome recorded
Phase 1 NCT01369602 Jul 2011 → Feb 2012 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01369277 Jun → Sep 2011 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01351129 May → Jun 2011 — Pfizer Completed No outcome recorded
Phase 1 NCT01129258 Jun → Dec 2010 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 1 NCT01102673 Apr → Jun 2010 type 2 diabetes mellitus Pfizer Completed No outcome recorded
Phase 22 trials · 2 met primary
Phase 2 NCT01338870 Jun 2011 → Mar 2012 type 2 diabetes mellitus Pfizer Completed Met primary
Phase 2 NCT01336738 Jun 2011 → Mar 2012 type 2 diabetes mellitus Pfizer Completed Met primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as PF-04991532 “A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of 2 Different Formulations Of PF-04991532” NCT01388829 ↗
10

“Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers” NCT01351129 ↗

NCT01370343 ↗

NCT01469065 ↗

NCT01129258 ↗

NCT01102673 ↗

NCT01469481 ↗

NCT01369277 ↗

NCT01336738 ↗

NCT01369602 ↗

NCT01338870 ↗
Action Activate “Hexokinase type IV activator” CHEMBL2165620 ↗
Modality Small molecule — CHEMBL2165620 ↗
Route Oral “single escalating oral doses” NCT01102673 ↗
Target GCK “Hexokinase type IV activator” CHEMBL2165620 ↗